Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANDA Bioequivalence Data Subject Of Upcoming FDA Proposed Rule

This article was originally published in The Tan Sheet

Executive Summary

FDA expects to issue an advance notice of proposed rulemaking in November requiring ANDA applicants to include data from all bioequivalence studies conducted on a drug formulation with their application

You may also be interested in...



AER Toll-Free Number Proposed Rule Targeted For September Release

The targeted action date for a proposed rule requiring the labeling of human drugs to carry a toll-free number for reporting adverse events has been pushed back to September, according to FDA's semi-annual "1unified agenda.

AER Toll-Free Number Proposed Rule Targeted For September Release

The targeted action date for a proposed rule requiring the labeling of human drugs to carry a toll-free number for reporting adverse events has been pushed back to September, according to FDA's semi-annual "1unified agenda.

AER Toll-Free Number Proposed Rule Targeted For September Release

The targeted action date for a proposed rule requiring the labeling of human drugs to carry a toll-free number for reporting adverse events has been pushed back to September, according to FDA's semi-annual "1unified agenda.

Related Content

Topics

UsernamePublicRestriction

Register

PS094020

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel